Application development of the molecular targeted therapy sorafenib for thyroid carcinoma

doi:10.3877/cma.j.issn.1674-0793.2016.03.017

Abstract

Abstract:

Part of radioactive iodine-refractory and special pathological types of thyroid cancer lacks effective treatment, leading to poor outcomes. Clinical studies of sorafenib treatment for thyroid cancer have been subjected to many domestic and international medical centers, most of which have entered the phase 2 and 3 clinical trials, including advanced differentiated thyroid cancer, medullary carcinoma, and anaplastic carcinoma. In some clinical trials, sorafenib has improved median progression-free survival (PFS), objective response (OR) rate, but the impact on overall survival (OS) is inconclusive. This article will focus on the mechanisms of sorafenib, treatment and adverse reactions, to discuss the progression of sorafenib for the treatment of thyroid cancer.

Key words: Thyroid neoplasms, Carcinoma, papillary, Carcinoma, medullary, Molecular mechanisms of pharmacological action, Treatment outcome

Haiqing Sun, Lixin Jiang, Baoyuan Li, Haitao Zheng. Application development of the molecular targeted therapy sorafenib for thyroid carcinoma[J]. Chinese Archives of General Surgery(Electronic Edition), 2016, 10(03): 227-230.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhptwkxwx.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-0793.2016.03.017

https://zhptwkxwx.cma-cmc.com.cn/EN/Y2016/V10/I03/227

References 31

1	Pitoia F. Response to sorafenib treatment in advanced metastatic thyroid cancer[J]. Arq Bras Endocrinol Metabol, 2014, 58(1): 37-41.
2	Capdevila J,Argiles G,Rodriguez-Frexinos V, et al. New ap-proaches in the management of radioiodine-refractory thyroid can-cer: the molecular targeted therapy era[J]. Discov Med, 2010, 9(45):153-162.
3	Thomas L,Lai SY,Dong W, et al. Sorafenib inmetastatic thyroid cancer: a systematic review[J]. Oncologist, 2014, 19(3): 251-258.
4	MacCorkle RA,Tan TH. Mitogen-activated protein kinases in cell-cycle control[J]. Cell BiochemBiophys, 2005, 43(3): 451-461.
5	Santoro M,Melillo RM,Fusco A. RET/PTC activation in papillary thyroidcarcinoma: European Journal of Endocrinology Prize Lec-ture[J]. Eur J Endocrinol, 2006, 155(5): 645-653.
6	Pak K,Suh S,Kim SJ, et al.Prognostic value of genetic mutations in thyroid cancer: a meta-analysis[J]. Thyroid, 2015, 25(1): 63-70.
7	Pelizzoa MR,Dobrinja C,CasalIdea E, et al. The role of BRAF(V600E) mutation as poor prognostic factor for the outcome of pa-tients with intrathyroid papillary thyroid carcinoma[J]. Biomed Pharmacotherapy, 2014, 68(4): 413-417.
8	石臣磊,秦华东.乳头状甲状腺癌与BRAF基因相关性的研究进展[J].中国普通外科杂志, 2014, 23(5): 675-679.
9	Yarchoan M,LiVolsi VA,Brose MS. BRAF mutation and thyroid cancer recurrence[J]. J Clin Oncol, 2015, 33(1): 7-8.
10	于洋,高明.甲状腺癌分子靶向治疗进展[J].中国肿瘤防治杂志, 2008, 15(8): 632-634.
11	Brose MS,Nutting CM,Jarzab B, et al. Sorafenib in radioactive io-dine-refractory, locally advanced or metastatic differentiated thy-roid cancer: a randomised, double-blind, phase 3 trial[J]. Lancet, 2014, 384(9940): 319-328.
12	Shen CT,Qui ZL,Luo QY. Sorafenib in the treatment of radioio-dine-refractory differentiated thyroid cancer: a meta-analysis[J]. Endocr Relat Cancer, 2014, 21(2): 253-261.
13	Marotta V,Ramundo V,Camera L, et al. Sorafenib in advanced io-dine-refractory differentiated thyroid cancer: efficacy, safety and exploratory analysis of role of serum thyroglobulin and FDG-PET[J]. ClinEndocrinol (Oxf), 2013, 78(5): 760-767.
14	Hoftijzer H,Heemstra KA,Morreau H, et al. Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma[J]. Eur J Endocri-nol, 2009, 161(6): 923-931.
15	Bellesoeur A,Carton E,Mir O, et al. Critical role Of sorafenib ex-posure over time for its antitumor activity in thyroid cancer[J]. In-vest New Drugs, 2014, 32(3): 569-572.
16	Boudou-Rouquette P,Ropert S,Mir O, et al. Variability of sorafenib toxicity and exposure over time: a pharmacokinetic/phar-macodynamic analysis[J]. Oncologist, 2012, 17(9): 1204-1212.
17	Brose MS,Nutting C,Shong YK, et al. Association between tumor BRAF and RAS mutation status and clinical outcomes in patients with radioactive iodine (RAI)-refractory differentiated thyroid can-cer (DTC) randomized to sorafenib or placebo: sub-analysis of the phase Ⅲ DECISION trial[C]. ECCO/ESMO/ESTRO Annual Meet-ing, Amsterdam, 2013.
18	Lam ET,Ringe MD,Kloos RT, et al. Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer[J]. J Clin Oncol, 2010, 28(14): 2323.
19	Capdevila J,Iglesias L,Halperin I, et al. Sorafenib in metastatic thyroid cancer[J]. Endocr Relat Cancer, 2012, 19(2): 209-216.
20	Savvides P,Nagaiah G,Lavertu P, et al. Phase II trial of sorafenib in patients with advanced anaplastic carcinoma of the thyroid[J]. Thyroid, 2013, 23(5): 600-604.
21	严丽,冀宏.索拉非尼对甲状腺未分化癌细胞增殖、迁移及侵袭能力的影响[J].中国医院药学杂志, 2014, 34(19): 1631-1634.
22	Mir O,Coriat R,Blanchet B, et al. Sarcopenia predicts early dose-limiting toxicities and pharmacokinetics of sorafenib in patients with hepatocellular carcinoma[J]. PLoS One, 2012, 7(5): e37563
23	Huillard O,Mir O,Peyromaure M, et al.Sarcopenia and body mass index predict sunitinib-induced early dose-limiting toxicities in renal cancer patients[J]. Br J Cancer, 2013, 108(5): 1034-1041.
24	Azad NS,Aragon-Ching JB,Dahut WL, et al. Hand-foot skin re-action increases with cumulative sorafenib dose and with combina-tion anti-vascular endothelial growth factor therapy[J]. Clin Can-cer Res, 2009, 15(4): 1411-1416.
25	Zhang L,Zhou Q,Ma L, et al. Meta-analysis of dermatological tox-icities associated with sorafenib[J]. Clin Exp Dermatol, 2011, 36(4): 344-350.
26	Ren Z,Zhu K,Kang H, et al. A randomized controlled phase II study of the prophylactic effect of urea-based cream on the hand-foot skin reaction associated with sorafenib in advanced hepatocel-lular carcinoma[C]. Annual Meeting of the American Society of Clinical Oncology, 2012, abstract no. 4008.
27	Dadu R,Waguespack SG,Sherman SI, et al. Efficacy and tolera-bility of different starting doses of sorafenib in patients with differ-entiated thyroid cancer[J]. Oncologist, 2014, 19(5): 477-482.
28	Ohba K,Takayama T,Matsunaga H, et al. Inappropriate elevation of serum thyrotropin levels in patients treated with axitinib[J]. Thy-roid, 2016, 23(4): 443-448.
29	Clemons J,Gao De,Naam M, et al. Thyroid dysfunction in patients treated with sunitinib or sorafenib[J]. Clin Genitourin Canc, 2012, 10(4): 225-231.
30	Je Y,Schutz FA,Choueiri TK. Risk of bleeding with vascular en-dothelial growth factor receptor tyrosine-kinaseInhibitors suni-tinib and sorafenib:a systematic review and meta-analysis of clini-cal trials[J]. Lancet Oncol, 2009, 10(10): 967-974.
31	Sherman EJ,Ho AL,Fury MG, et al. Phase II study of everolimus and sorafenib for the treatment of metastatic thyroid cancer[J]. J ClinOncol, 2013, 31(15suppl): 6024.

[1]	Zhengwen Xu, Zhen Li, Zhenyang Hou, Changzheng Su, Biao Zhu. Platelet rich plasma combined with bone grafting for treatment of early non-traumatic osteonecrosis of femoral head [J]. Chinese Journal of Joint Surgery(Electronic Edition), 2023, 17(06): 773-779.
[2]	Hongyu Wang. Application value of fixed and mobile platform prostheses in total knee arthroplasty [J]. Chinese Journal of Joint Surgery(Electronic Edition), 2023, 17(06): 871-876.
[3]	Shanwu Li, Yongjie Ye, Bing Wang, Ziyi Wang, Yi Yin, Guanjun Sun, Dagang Zhang. Early efficacy comparison of open wedge high tibial osteotomy and unicompartmental knee arthroplasty [J]. Chinese Journal of Joint Surgery(Electronic Edition), 2023, 17(06): 882-888.
[4]	Zeyong Wang, Jian Qin. Effect of white blood cell content on platelet-rich plasma treatment of motor system injuries [J]. Chinese Journal of Joint Surgery(Electronic Edition), 2023, 17(05): 684-688.
[5]	Yonghao Li, Xuefei Gao, Tiantian Guo, Jin Zhang, Caizhen Zhang, Jing Liu. Advances in the research of mechanisms related to obesity combined with thyroid carcinoma [J]. Chinese Archives of General Surgery(Electronic Edition), 2023, 17(04): 311-315.
[6]	Zhenjian Jiang, Ming Jiang, Dali Huang. The expression and prognostic value of TK1 and Ki67 proteins in differentiated thyroid carcinoma [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2023, 17(06): 623-626.
[7]	Hui Huang, Xinqiang Zhu. Efficacy and influencing factors of ¹³¹I in the treatment of differentiated thyroid carcinoma under 45 years old [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2023, 17(06): 627-630.
[8]	Lichao Fan, Jinying Guo, Xin Chen. The significance of detection of wild-type RET and RET/PTC fusion gene for lymph node dissection in the central region of papillary thyroid carcinoma [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2023, 17(06): 631-635.
[9]	Haitao Zhang, Chanjuan Kang, Jingjie Zhai. Effect of pancreatic duct stent implantation in the treatment of acute biliary pancreatitis [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2023, 17(06): 654-657.
[10]	Cheng Xu, Lulu Wang, Shaohua Wang. Application of eluent thyroglobulin in metastatic lymph nodes of thyroid papillary carcinoma [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2023, 17(06): 701-704.
[11]	Yutao Yuan, Jinlin Xing, Kefei Xie, Kai Yin. Correlation between CT findings and BRAF^V600E gene mutation and central lymph node metastasis in papillary thyroid carcinoma [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2023, 17(06): 611-614.
[12]	Zhanbin Cui, Junli Qiao, Lili Zhang, Mingqiang Han. Correlation between urinary iodine levels and stratified risk of recurrence in patients with papillary thyroid cancer after surgery [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2023, 17(06): 615-618.
[13]	Yao Chen, Boqun Xu, Zhihui Gao. Efficacy and safety of modified intermediate upper approach radical resection in the treatment of thyroid cancer [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2023, 17(06): 619-622.
[14]	Yi Wang, Sizhe Xu, Zhangxia Ren. Effect of endoscopic unilateral thyroid lobectomy via thoracic breast approach and open surgery on postoperative recovery in patients with differentiated thyroid cancer [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2023, 17(05): 542-545.
[15]	Fengjie Wang, Liguang Wang, Shan Liao, Ying Liu, Rongdang Fu, Huanwei Chen. Safety and efficacy of laparoscopic right hemihepatectomy for hepatocellular carcinoma [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2023, 12(05): 517-522.

Please choose a citation manager

Content to export